Xintaige Asset Management

Founder Wang Hongxin leads investment decisions. Public records identify Wang as the firm's central decision-maker since its 2008 founding. Xintaige's organizational structure is not publicly disclosed, so the extent of supporting investment staff or formal committee processes remains undocumented.

Xintaige concentrates on seed-stage and pre-IPO investments, according to public filings. This dual-end focus allows the firm to access technology at its earliest institutional entry point and to capture late-stage value before public listing. The firm does not appear to participate in Series A through Series C rounds as a standard practice.

Xintaige invests in enterprise software, artificial intelligence and machine learning, industrial technology, and digital health. Publicly documented portfolio companies include Yuanxin Technology, a health-tech platform, and Shenzhen New Industries Biomedical Engineering, a diagnostic equipment maker. The firm does not target consumer internet, e-commerce, or real estate.

Xintaige sources deals through China's formal research infrastructure — university labs, state-backed technology incubators, and industrial research consortia. This institutional pipeline gives the firm early visibility into technology transfer projects before they appear on traditional venture-capital radars. The approach contrasts with network-based or auction-driven deal origination common among peer firms.

No. Xintaige does not publicly disclose assets under management, total deployment, or fund-level performance. The firm operates with the opacity typical of domestic Chinese private equity managers that do not market to international institutional LPs.

Xintaige concentrates on Greater China, with deal flow originating from Beijing, Shanghai, and Shenzhen. The firm's investment mandate does not publicly include cross-border investments or offshore structures, though some portfolio companies may eventually pursue overseas listings.

Xintaige has backed companies including Yuanxin Technology, a digital-health platform, and Shenzhen New Industries Biomedical Engineering, which subsequently listed on the Shenzhen Stock Exchange. Beyond these publicly identifiable names, the firm's broader portfolio and exit track record are not systematically disclosed in English-language sources.